Tagged with

Bausch & Lomb Poland BAUSCH + LOMB has over 150 years of heritage and has always been associated with optics and ophthalmology. Therefore the company has been able to build a very strong brand image throughout the years and is today recognized as the best in eye health. Would you say it is an…

AstraZeneca Poland You have been quite recently appointed at the head of the Polish affiliate of AstraZeneca. With which personal ambitions did you come and what was the mission you were given when you took office? I would not say that I have been given a mission, but that I have been…

Pró Genéricos When we last interviewed you in 2007, you said, “The generics business is a very exciting one,” but you “regret[ted] that the Government is not doing enough work to promote it.” At that time, generics penetration was around 10.5% – now it’s around 20%. Does this reflect some fundamental change…

IMS Health Brazil We know the raw data already in the Brazilian market and the number changes since our last visit in 2007 – but how would you interpret these changes into a coherent story explaining the evolution since that time in the country’s pharmaceutical history? The one major factor influencing country growth…

GlaxoSmithKline Colombia Michael Sean Reilly: General Manager for Pharmaceuticals Juan Carlos Berbessi: Medical Director Maria del Pilar Rubio: Medical Manager for Vaccines Gustavo Zapata: Finance Director Juan Pablo Restrepo: Legal Affairs Manager What is the strategic role and importance of Colombia within the larger global framework of GlaxoSmithKline (GSK)? Michael Sean Reilly:…

Bayer Schering Pharma The 2006 acquisition of Schering by Bayer is a prime example of the way that big pharma is now approaching growth through acquisition in this extremely competitive and challenging global market. Given that the company seems to be finished with mergers and acquisitions for the time being, what are Bayer…

Cegedim Poland Given Cegedim’s global reach and your 13 year experience of operating as a consultant to the Polish pharma industry, how would you describe the market to the international readers of Pharmaceutical Executive? On the one hand the pressures and incentives influencing the main stakeholders are the same as elsewhere. But…

GSK Brazil You’ve made some bold moves in your career – from the head of vaccines in Latin America, followed by stints in Colombia, Puerto Rico, and finally Brazil. What brought you along that trajectory, and what have been some of the most important milestones since your arrival here in 2008? I…

Productos Roche S.A. What has been the evolution of Roche’s operations in Colombia’s over the course of its proud 52-year history here? As with almost all pharmaceutical companies with commercial operations in Latin America, we began our business here in Colombia with a production plant. The plant has closed since 1997 as our…

Baxter Chile Baxter Chile established itself in the country through the acquisition of a local manufacturer in 1995. What have been the main challenges for the company as a local manufacturer? Chile is a market with many opportunities. For Baxter in Chile, our biggest challenge is maintaining a competitive pricing strategy while…

Farmindustria & Laboratorio Volta As the CEO of Farmindustria since 1998, what would you say has been your recipe for the impressive success that the company has experienced, considering that Farmindustria represents 35% of all contract manufacturing activities in Chile? Our strongest key to success has certainly been the team that work’s here. Manufacturing…

Astellas Poland You were appointed general manager of Astellas Poland in early 2006, only a bit after Astellas Pharma Inc. was established, on April 1, 2005 through the merger of the mother companies Yamanouchi and Fujisawa. Could you describe to our readers the evolution of the affiliate since the merger? Astellas has…